Bisphosphonates in early breast cancer
Mené sur 3 323 patientes atteintes d'un cancer du sein de stade 1-3, cet essai multicentrique randomisé évalue, du point de vue de la survie sans maladie, l'efficacité d'un bisphosphonate par voie orale, le clodronate (durée médiane de suivi: 90,7 mois)
In breast cancer treatment, our main focus has remained steadfast on structural, molecular, or functional features of the tumour itself. Clinical and experimental evidence, however, indicates that the complex cycle of tumour formation, growth, and dissemination is an interaction between the cancer cell and the diseased host. In The Lancet Oncology, Alexander Paterson and colleagues report final results of the National Surgical Adjuvant Breast and Bowel Project's protocol B-34 study. In this phase 3 randomised clinical trial undertaken in women with early breast cancer, the investigators targeted the bone microenvironment rather than the tumour with the oral bisphosphonate clodronate.
The Lancet Oncology , commentaire en libre accès, 2011